logo
EVast Bio Achieves World's First Exosome Therapy Application for Knee Osteoarthritis

EVast Bio Achieves World's First Exosome Therapy Application for Knee Osteoarthritis

Yahoo06-03-2025

MIAMI, March 05, 2025 (GLOBE NEWSWIRE) -- EVast Bio, a U.S.-based clinical-stage biotech company, has achieved an important milestone by conducting the world's first human application of small extracellular vesicles (sEV) also called exosomes for osteoarthritis (OA) - EVA-100. According to a recent study published in the Journal of Nanobiotechnology, this achievement demonstrates promising results in inflammation control and cartilage protection offering a new therapeutic option for millions of patients suffering from OA. The research showcases a comprehensive development pipeline, from concept to first-in-human validation, marking a significant breakthrough in the treatment of knee osteoarthritis using clinical-grade sEV.
Osteoarthritis, a debilitating joint disease characterized by cartilage degradation and chronic inflammation, affects millions worldwide. Current treatments primarily focus on symptom management. This new study introduces a novel therapeutic approach using small extracellular vesicles (sEV) derived from umbilical cord mesenchymal stromal cells (UC-MSC) offering a potentially longer-lasting disease-modifying benefit.
'Our research marks a significant advancement in anti-inflammatory therapeutics with dual protective and regenerative potentials for osteoarthritis treatment,' the research team explains. 'We've developed a standardized, reproducible process for manufacturing clinical-grade extracellular vesicles, demonstrating remarkable potential in both preclinical and initial human studies,' comment Dr. Maroun Khoury, co-founder and Chief Scientific Officer of EVast Bio.
'EVA-100 could revolutionize osteoarthritis treatment, offering a transformative solution for millions if preclinical results are confirmed in both safety and efficacy clinical trials. Our approach aims to go beyond symptom relief by exploring the potential for cartilage regeneration, a key differentiator from existing therapies,' commented Matías Vial, Co-founder & CEO of EVast Bio.
Key Research Findings:
Innovative Manufacturing Process
The team established a standardized manufacturing protocol that meets Good Manufacturing Practice (GMP) standards, ensuring consistent production of clinical-grade sEV. This achievement marks a crucial step in bridging the gap between laboratory research and clinical application.
Highly Reproducible and Standardized sEV Manufacturing at EVast Bio
EVast Bio's proprietary platform has demonstrated a high level of reproducibility and standardization in the production of small extracellular vesicles (sEVs). Advanced molecular profiling of our sEVs has identified a consistent set of microRNAs (miRNAs) and proteins, reinforcing their stability and reliability for therapeutic applications. Notably, our research shows that a core group of highly specific miRNAs and proteins is consistently present across multiple donor-derived sEV samples.
Mechanism of Action
The study provides insights into how sEV combat osteoarthritis at the cellular level. Our researchers discovered that EVA-100 create an anti-inflammatory environment within affected joints by strategically guiding macrophages toward an anti-inflammatory state. This mechanism is supported by comprehensive miRNA and proteome analysis, highlighting the sophisticated molecular approach of the treatment.
A recently published study by the the Western Ontario Registry for Early OA (WOREO) Knee Study team suggests that while synovitis increases in OA, the exhaustion and dysfunction of immune-regulatory macrophages are linked to greater pain, making them a promising therapeutic target.
Preclinical Success
In preclinical studies using an OA mouse model, intra-articular injection of EVA-100 demonstrated positive therapeutic effects including hyaline cartilage regeneration – restoring joint function and mobility, a prolonged retention of sEV in the knee joint – ensuring sustained therapeutic action.
Pioneering a New Standard for OA Treatment
The therapy, EVA-100, leverages clinical-grade sEV derived from umbilical cord mesenchymal stromal cells (UC-MSC) and has shown transformational potential. Key highlights include:-World-First Human Application: EVA-100 was administered to a 56-year-old OA patient, achieving a significant WOMAC score reduction within six months and validated cartilage regeneration through third-party evaluation.-Regenerative Impact: Evidence of increased cartilage volume (WATSc) six months post-treatment underscores the therapy's capacity to restore joint health.-Strong Safety Profile: No adverse effects were reported during a 12-month follow-up, further validating the therapy's suitability for continued clinical development.
Beyond Osteoarthritis: A Next-Generation Drug Delivery Platform for small molecules.
EVast Bio's proprietary exosome-based platform extends far beyond osteoarthritis, offering a vehicle for advanced drug delivery across multiple therapeutic areas. By leveraging the natural tissue-targeting, immune-modulating, and cargo-loading capabilities of extracellular vesicles (EVs), EVast Bio is developing engineered exosomes designed for targeted delivery of small molecules, RNA therapeutics, and biologics. This customized approach has the potential to enhance bioavailability, reduce systemic toxicity, and enable new treatment strategies in oncology, neurodegenerative diseases, metabolic disorders, and autoimmune conditions.
With a robust GMP-compatible manufacturing process, strong IP portfolio, and growing clinical pipeline, EVast Bio is connecting with pharma and biotech partners to co-develop next-generation EV-based therapeutics that go beyond traditional drug delivery methods.
A Commercial Model Driving Innovation
EVast Bio is leading the exosome revolution in regenerative medicine with a clear strategy for commercialization and expansion:-Advanced Clinical Trials: EVA-100 is currently in Phase I trials (NCT06431152) with a dose-escalation protocol designed to refine safety and efficacy metrics.-Promising Results: Combined preclinical and clinical data showcase potential for cartilage repair and long-term joint health.-Pipeline Expansion: EVA-100+ is under development as an advanced drug-loaded exosome, including RNA loading targeting age-related conditions.-Strategic Partnerships: Actively pursuing collaborations to scale and license its proprietary sEV technology
Looking Ahead
The successful development and validation of this novel therapeutic approach opens new possibilities for OA treatment but also reinforces EVast Bio's position as a global leader in regenerative medicine and extracellular vesicle (EV) therapies. The research team has already initiated an early-phase clinical trials initiated this year; as detailed in the recently published, peer reviewed study.
'This comprehensive research pipeline, from development through preclinical testing to initial human validation, provides a strong foundation for advancing extracellular vesicle therapy in clinical practice,' the researchers note. 'The potential to offer a safe, effective, and locally-administered treatment for osteoarthritis patients represents a significant step forward in regenerative medicine,' highlights Dr. Maroun Khoury, who is also IMPACT Center director and CSO of Cells for Cells (C4C)—the center of excellence and biotech company sponsoring the study. C4C, the parent company from which EVast Bio was born, has played a crucial role in pioneering this innovation. EVast Bio, its US-based spinoff, presented the groundbreaking results of the first clinical case and trial design evaluating the safety and efficacy of EVA-100. These findings were showcased at prominent conferences, including ISCT and ISEV meetings held in San Francisco, Paris, Lyon, and Vancouver.
To fully leverage its exosome platform, C4C is launching a US-based spinoff focused on osteoarthritis (OA) and longevity. This new venture seeks to raise $18 million to fund the Phase IB studies of EVA-100 and accelerate the development of EVA-100+, an advanced drug-loaded exosome therapy targeting age-related conditions. The company is also pursuing co-development partnerships and expanding its portfolio with customized membrane-engineered and drug-loaded exosomes for additional therapeutic indications based on partners' interest. This strategic initiative strengthens EVast Bio as a leader in the $2.8 billion US exosomes market, aiming to deliver disease-modifying therapies to an estimated six million eligible patients. In osteoarthritis alone, the Serviceable Addressable Market (SAM) in the US is estimated at $7 billion, highlighting the vast commercial potential of exosome-based therapies in this space.
About the Research
Published in Journal of Nanobiotechnology (volume 23, Article number: 13, 2025), this study represents a collaborative effort to address one of the most common joint diseases affecting global health. The research combines expertise in regenerative medicine, cell biology, and clinical translation to develop an innovative therapeutic approach for osteoarthritis treatment.
For more information, please refer to the full study in the, Journal of Nanobiotechnology,
https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-024-03088-x
About EVast Bio: www.evast.bio
EVast Bio is a US-based clinical-stage biotech spinoff of Cells for Cells and Delaware C Corp pioneering the development of small Extracellular Vesicle (sEV) therapeutics. The proprietary platform harnesses these natural nano-vehicles – microscopic particles released by cells that facilitate intercellular communication – to create next-generation targeted delivery systems. The company innovative approach combines advanced sEV selection technology with precision engineering to develop therapeutics with enhanced safety and efficacy profiles. Through our patented technology, we produce sEVs with unique molecular signatures specifically tailored to target disease pathways. By optimizing drug delivery and reducing adverse events, EVast Bio is transforming the treatment landscape for challenging diseases. Our international clinical-stage pipeline demonstrates the potential of sEV technology to revolutionize therapeutic delivery and advance precision medicine.
About Cells for Cells:
C4C. (www.c4c.cl) is a clinical-stage company developing biotechnology platforms in South-America, including allogeneic cell therapies and extracellular vesicles. The company's mission is to enhance global healthspan by addressing key hallmarks of high-prevalence chronic diseases.
C4C previously raised $40 million USD, reinforcing its leadership in the biotechnology sector and accelerating the development of innovative therapies to improve patient outcomes worldwide. C4C is committed to time-sensitive and cost-efficient clinical and IP validation, a strategy that enable it to the first-ever clinical proof-of-principle of an exosome-produced therapy targeting joint disease.
Contact:CEO: mvial@c4c.clScientific related interest: maroun@evast.bioBusiness development interest: dsegura@c4c.cl

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Historic Win for Foster Youth and Families: A New Medicaid Benefit Becomes Reality
Historic Win for Foster Youth and Families: A New Medicaid Benefit Becomes Reality

Yahoo

timean hour ago

  • Yahoo

Historic Win for Foster Youth and Families: A New Medicaid Benefit Becomes Reality

Los Angeles, CA, June 10, 2025 (GLOBE NEWSWIRE) -- Special Needs Network is proud to announce a major policy victory that will change lives across California. Thanks to our leadership and collaboration with state partners, a brand-new Medicaid benefit – the Fee-for-Service Behavioral Health Treatment (FFS BHT) benefit – will launch statewide on July 1, 2025. The new provider enrollment portal is open so providers can be ready to serve patients day one. SNN will be ready. 'This is a monumental step forward for California's foster youth and families,' said Areva Martin, President of Special Needs Network. 'Creating a brand-new Medicaid benefit in record time shows what's possible when community advocates, policymakers, and government agencies work together. We are proud that Special Needs Network's leadership helped drive this historic change — and we remain committed to ensuring that every child gets the care and support they deserve.' This breakthrough ensures that foster youth and all other children needing behavioral health therapy will finally have direct access to services under Medi-Cal, with more providers available and fewer barriers to care.,. Access will no longer be determined by whether a child has a managed care plan or FFS Medi-Cal or whether they are served by a regional center or not. Creating this new benefit involved: Securing federal approval for a new Medicaid State Plan. Building a statewide provider enrollment system. Establishing new billing codes and payment systems. Ensuring access for smaller community organizations and paraprofessionals. Eliminating referral barriers for families, physicians, and courts. SNN played a critical role at every step, providing technical expertise, real-world feedback, and advocacy that state officials have called 'invaluable.' Although the benefit launches July 1, work continues to refine the system and fully support providers, youth, and families. SNN will remain deeply involved in training, communications, system improvements, and monitoring to ensure a smooth rollout and lasting success. Priority processing is available through June 30. See the FAQs for providers here 'This win represents one of the fastest and most significant Medicaid benefit developments in California history — and it was fueled by SNN's dedication to children, families, and equitable access to care,' said Kristin Jacobson, a policy expert and long-time advocate who participated in this effort on behalf of SNN. To submit a PAVE application, agencies need to visit the PAVE (Provider Application and Validation for Enrollment) system portal: _________________________________________________________________________ (SNN) is a nonprofit grassroots organization responding to the crisis of autism and other developmental disabilities in underserved communities. We recognize the intersectionality of individuals with disabilities and that their fight for disability rights is inextricably tied to the fight for racial justice and the civil rights of all people. CONTACT: Special Needs Network communications@

Enhance.MD Launches Nationwide Telehealth Expansion to Support Men's Hormonal Health and Medically Supervised Weight Loss
Enhance.MD Launches Nationwide Telehealth Expansion to Support Men's Hormonal Health and Medically Supervised Weight Loss

Yahoo

timean hour ago

  • Yahoo

Enhance.MD Launches Nationwide Telehealth Expansion to Support Men's Hormonal Health and Medically Supervised Weight Loss

Virtual platform now offers licensed physician care for testosterone therapy, GLP-1 weight loss support, and men's wellness programs across all 50 U.S. states San Diego, June 10, 2025 (GLOBE NEWSWIRE) -- a U.S.-based telehealth provider specializing in men's hormonal optimization and metabolic wellness, has officially expanded its clinical care services nationwide. This expansion supports a growing number of men seeking personalized healthcare solutions for low testosterone, weight challenges, and performance-related health issues—all from the convenience of their own home. Through its secure platform, connects patients to licensed U.S. physicians who evaluate medical history, review lab work, and prescribe clinically appropriate treatment programs. The company's services now reach patients in all 50 states, including those in remote or underserved areas where access to specialized care may be limited. 'Our mission is to make medically supervised hormone therapy and weight loss care more accessible for men everywhere,' said a spokesperson for 'This nationwide expansion reflects our commitment to safe, evidence-based telemedicine that empowers patients to take charge of their long-term health.' virtual platform is designed for ease of use, featuring: Fast, secure medical intake and scheduling Lab partnerships for at-home or local diagnostic testing Ongoing provider monitoring and patient support HIPAA-compliant communication channels Nationwide medication delivery where legally permitted All care is provided by board-certified physicians and licensed healthcare professionals who follow strict clinical guidelines. Treatment options may include testosterone replacement therapy (TRT), GLP-1-based metabolic weight programs, and supportive interventions for men's health, always following a personalized and physician-reviewed protocol. With recent updates to its website and mobile user interface, has also improved patient onboarding, reduced consultation wait times, and expanded clinical support availability. About is a telehealth company focused on optimizing men's health through medical evaluation, diagnostic testing, and customized treatment plans. The company specializes in testosterone therapy, weight management, and performance-focused wellness protocols—delivered entirely online through licensed U.S. providers. By combining technology with medical oversight, empowers men to pursue health goals with professional guidance and national reach. Contact: AM – 8:00 PM EDT Monday – Friday9:00 AM – 5:00 PM EDT Saturday – Sunday16776 Bernardo Center Dr. Suite 203, San Diego, CA 92128https:// SOURCE: Disclaimer This press release is for informational purposes only. provides healthcare services under licensed clinical supervision in compliance with state and federal regulations. No part of this release should be interpreted as medical advice or a substitute for an in-person doctor consultation. Treatment eligibility, outcomes, and availability may vary based on individual patient circumstances and state-specific regulations. CONTACT: 1-888-299-5088 support@ 8:00 AM – 8:00 PM EDT Monday – Friday 9:00 AM – 5:00 PM EDT Saturday – SundayError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties

Yahoo

timean hour ago

  • Yahoo

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties

Consideration composed of a $350m up-front payment and up to $1.0bn in development, regulatory and commercial milestones, along with mid-single to low double-digit royalties on Global Net Sales OTELFINGEN, Switzerland, June 10, 2025 (GLOBE NEWSWIRE) -- Philochem AG ("Philochem'), a wholly-owned subsidiary of the Philogen Group (MIL:PHIL), and RayzeBio, Inc. ('RayzeBio'), a wholly-owned subsidiary of Bristol-Myers Squibb company (NYSE: BMY), today announced a definitive agreement under which Philochem will license the exclusive worldwide rights to develop, manufacture, and commercialise OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer, to RayzeBio. OncoACP3 is a small molecule ligand with high affinity and specificity for Acid Phosphatase 3 (ACP3), a novel target in prostate cancer. The compound is currently under evaluation in a company-sponsored Phase I trial (NCT06840535). Initial data from the first cohort of patients evaluated with the OncoACP3 diagnostic has been promising, displaying selective tumour uptake and long residence time with minimal healthy tissue uptake. IND-enabling activities to support the application for a Phase I therapeutic study with 225Ac-OncoACP3 are ongoing. Prof. Dr. Dario Neri, CEO and CSO of Philogen, commented: 'We are delighted to enter into this new collaboration with RayzeBio, a leader in the field of radiopharmaceutical medicines. This partnership will focus on the development and commercialization of OncoACP3 for both diagnostic and therapeutic applications in prostate cancer. OncoACP3 is a best-in-class targeting agent with the potential to become a breakthrough treatment in this field. This collaboration reflects our shared commitment to translating scientific innovation into meaningful clinical solutions, making OncoACP3 therapies widely available to patients in need.' Ben Hickey, President, RayzeBio commented: 'This collaboration with Philochem enhances our leadership in the rapidly advancing radiopharmaceuticals space, consistent with our strategy to bring forward best-in-class RPT candidates. OncoACP3, with its initial encouraging safety profile, provides a differentiated entry for Bristol Myers Squibb and RayzeBio into the prostate cancer arena, building on our leadership in actinium-based RPT development. This agreement is a significant milestone for RayzeBio and our goal to deliver radiopharmaceuticals to patients.' Under the terms of the agreement, Philochem will receive an up-front payment of $350m and up to $1.0bn in development, regulatory and commercial milestones. The company will also receive mid-single to low double-digit royalties payable on Global Net Sales of both Therapeutic and Diagnostic agents of OncoACP3. The closing of the transaction is subject to regulatory approvals and other customary closing conditions. The parties expect that the agreement will close in the third quarter of 2025. For Philochem, Centerview Partners UK LLP is acting as exclusive financial advisor and Cooley LLP is acting as exclusive legal counsel. About Philogen group Philogen is an Italian-Swiss group active in the biotechnology sector, specialised in the research and development of pharmaceutical products for the treatment of highly lethal diseases. Philogen's mission is to discover, develop and market innovative pharmaceuticals for the treatment of diseases of high unmet need. This is achieved by exploiting (i) proprietary technologies for the isolation of ligands that react with antigens present in certain diseases, (ii) experience in the development of products targeted at the tissues affected by the disease, (iii) experience in drug manufacturing and development, and (iv) an extensive portfolio of patents and intellectual property rights. Although the Group's drugs are primarily oncology applications, the targeting approach is also potentially applicable to other diseases, such as certain chronic inflammatory diseases. FOR MORE INFORMATION Philogen - Investor Relations IR@ - Emanuele Puca | Investor RelationsError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store